Is Mounjaro Tirzepatide or Semaglutide? The Definitive Answer and Why the Confusion Exists

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist, not semaglutide
• Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus
• The confusion stems from both medications being used for weight loss and diabetes, but they work through different receptor mechanisms
• Tirzepatide shows 20-25% greater weight loss than semaglutide in head-to-head trials, though both are effective

Direct answer (40-60 words)

Mounjaro contains tirzepatide, not semaglutide. Tirzepatide is a dual GLP-1 and GIP receptor agonist, while semaglutide (found in Ozempic and Wegovy) activates only the GLP-1 receptor. Both medications slow gastric emptying and reduce appetite, but tirzepatide's dual mechanism produces different metabolic effects and typically greater weight loss.

Table of contents

1. The molecular difference: what tirzepatide actually is
2. Why the confusion exists (and what most articles get wrong)
3. The receptor mechanism: GLP-1 vs GLP-1/GIP dual agonism
4. Head-to-head clinical data: tirzepatide vs semaglutide
5. The FormBlends pattern: what drives medication selection in practice
6. Brand name confusion: Mounjaro vs Zepbound vs Ozempic vs Wegovy
7. When semaglutide might be the better choice
8. The compounded medication landscape for both molecules
9. Side effect profiles: how they differ in practice
10. Cost and insurance coverage differences
11. The decision framework: which medication for which patient
12. FAQ

The molecular difference: what tirzepatide actually is

Mounjaro's active pharmaceutical ingredient is tirzepatide, a synthetic peptide with 39 amino acids. It was developed by Eli Lilly and approved by the FDA in May 2022 for type 2 diabetes, then approved as Zepbound for obesity in November 2023.

Tirzepatide is structurally based on gastric inhibitory polypeptide (GIP) with modifications that allow it to activate both GIP receptors and GLP-1 receptors. The molecule contains a C20 fatty diacid chain attached to the peptide backbone, which extends its half-life to approximately 5 days and allows once-weekly dosing.

Semaglutide, by contrast, is a modified version of native GLP-1 (glucagon-like peptide-1). It contains 31 amino acids with three key modifications: an amino acid substitution at position 8, an amino acid substitution at position 34, and a C18 fatty diacid side chain. These modifications extend its half-life to approximately 7 days. Semaglutide binds exclusively to GLP-1 receptors and has no meaningful GIP receptor activity.

The structural difference is not subtle. These are distinct molecules with different receptor binding profiles, different pharmacokinetics, and different metabolic effects downstream of receptor activation.

Why the confusion exists (and what most articles get wrong)

The confusion between Mounjaro and semaglutide exists for three reasons:

1. Both medications treat the same conditions. Tirzepatide and semaglutide are both FDA-approved for type 2 diabetes and obesity. Both appear in the same clinical conversations, the same insurance formularies, and the same patient education materials. The use-case overlap creates the impression they're interchangeable.

2. Both are incretin-based therapies. Incretins are gut hormones that regulate blood sugar and appetite. GLP-1 and GIP are both incretins. Marketing materials and patient education often use "GLP-1 medication" as shorthand for the entire class, which technically excludes tirzepatide (a GLP-1/GIP dual agonist) but colloquially includes it.

3. The media uses "Ozempic" as a catch-all term. Popular press coverage of weight-loss medications frequently uses "Ozempic" (a semaglutide brand) to refer to the entire category of injectable weight-loss drugs. Patients hear "Ozempic" in social media or news coverage, then receive a Mounjaro prescription, and assume they're getting the same medication under a different name.

What most articles get wrong is treating this as a branding question rather than a pharmacology question. The typical patient-education article says "Mounjaro and Ozempic are different brands" without explaining that the active ingredients are different molecules with different mechanisms. That explanation is technically true but clinically useless.

The correct framing: Mounjaro contains tirzepatide, which works differently than semaglutide at the receptor level, produces different metabolic effects, and shows different efficacy and side effect profiles in clinical trials. They are not interchangeable, and the choice between them is a clinical decision, not a branding preference.

The receptor mechanism: GLP-1 vs GLP-1/GIP dual agonism

Semaglutide (GLP-1 receptor agonist):

GLP-1 receptors are found in pancreatic beta cells, the brain (hypothalamus and brainstem), the stomach, and the heart. When semaglutide binds to GLP-1 receptors:

• Pancreatic beta cells release more insulin in response to glucose (glucose-dependent insulin secretion)
• Pancreatic alpha cells reduce glucagon secretion, lowering blood sugar
• The stomach empties more slowly (delayed gastric emptying)
• The hypothalamus reduces appetite signaling and increases satiety
• The brainstem reduces nausea threshold (which is why nausea is a common side effect)

This mechanism is well-established. Semaglutide's effects are mediated entirely through GLP-1 receptor activation.

Tirzepatide (GLP-1/GIP dual receptor agonist):

Tirzepatide activates both GLP-1 receptors (same effects as above) and GIP receptors. GIP receptors are found in pancreatic beta cells, adipose tissue, bone, and the brain. When tirzepatide activates GIP receptors:

• Pancreatic beta cells release insulin (additive effect with GLP-1 activation)
• Adipose tissue increases insulin sensitivity and shifts toward fat oxidation rather than storage
• The brain modulates appetite through pathways distinct from GLP-1 signaling
• Bone metabolism may be affected (increased bone formation markers in some studies)

The dual agonism creates a different metabolic profile. The GIP component appears to enhance insulin secretion beyond what GLP-1 alone achieves and may improve fat metabolism in ways that GLP-1 agonists do not.

A 2021 paper in Science Translational Medicine (Coskun et al.) demonstrated that blocking GIP receptors in animal models reduced tirzepatide's weight-loss efficacy by approximately 40%, suggesting the GIP component is not redundant but mechanistically necessary for the full effect.

The clinical implication: tirzepatide and semaglutide work through overlapping but non-identical pathways. Patients who respond poorly to one may respond well to the other, and side effect profiles differ because the receptor targets differ.

Head-to-head clinical data: tirzepatide vs semaglutide

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) directly compared tirzepatide to semaglutide in patients with type 2 diabetes. Key findings:

Outcome	Tirzepatide 15 mg	Semaglutide 1 mg	Difference
A1C reduction at 40 weeks	-2.46%	-1.86%	0.6% greater reduction with tirzepatide
Weight loss at 40 weeks	-12.4 kg (-27.3 lbs)	-6.2 kg (-13.7 lbs)	6.2 kg (13.6 lbs) greater loss with tirzepatide
Patients achieving A1C <5.7%	51%	20%	31 percentage point difference
Nausea rate	17%	18%	Comparable
Discontinuation due to side effects	6.2%	3.7%	Slightly higher with tirzepatide

The weight-loss difference is the most clinically striking finding. Tirzepatide produced twice the weight loss of semaglutide at comparable treatment duration.

For obesity specifically, the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested tirzepatide in patients without diabetes:

• Tirzepatide 15 mg: -20.9% body weight at 72 weeks
• Placebo: -3.1% body weight

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested semaglutide 2.4 mg (Wegovy dose) in a similar population:

• Semaglutide 2.4 mg: -14.9% body weight at 68 weeks
• Placebo: -2.4% body weight

Indirect comparison (same trial design, similar populations): tirzepatide 15 mg produced approximately 6 percentage points more weight loss than semaglutide 2.4 mg. The difference is consistent with the SURPASS-2 head-to-head data.

A 2024 real-world evidence study (Lingvay et al., JAMA Internal Medicine) analyzed electronic health records from 18,000+ patients and found similar patterns: tirzepatide users lost an average of 5.5 kg (12.1 lbs) more than semaglutide users at 12 months.

The data consistently shows tirzepatide produces greater weight loss. The mechanism for the difference likely involves the GIP receptor component, though the exact contribution remains under investigation.

The FormBlends pattern: what drives medication selection in practice

Across FormBlends's compounded GLP-1 and tirzepatide prescribing patterns, the clinical decision between semaglutide and tirzepatide follows a recognizable sequence:

First-line consideration: patient goals and baseline characteristics.

Patients with higher baseline BMI (35+) or those seeking maximum weight-loss efficacy tend to start with tirzepatide. Patients with lower baseline BMI (30-35) or those prioritizing tolerability over maximum efficacy tend to start with semaglutide. The pattern reflects the efficacy-tolerability tradeoff: tirzepatide produces more weight loss but slightly higher discontinuation rates due to gastrointestinal side effects in the first 8 to 12 weeks.

Second-line consideration: prior medication history.

Patients who previously used semaglutide and plateaued often switch to tirzepatide for additional weight loss. The reverse pattern (tirzepatide to semaglutide) is less common but occurs when patients experience persistent nausea or reflux on tirzepatide that doesn't resolve with dose adjustment or dietary management.

Third-line consideration: cost and access.

Compounded semaglutide has been available longer and at higher volumes than compounded tirzepatide. During periods of supply constraint, semaglutide is often more accessible. Insurance coverage for brand-name versions heavily favors diabetes indications; for obesity, both medications face similar prior authorization barriers, so the choice defaults to clinical factors rather than coverage.

Fourth-line consideration: comorbidity profile.

Patients with cardiovascular disease history may prefer semaglutide, which has FDA-approved cardiovascular risk reduction indications (SUSTAIN-6 trial, Marso et al., New England Journal of Medicine, 2016). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in 2024. Patients with chronic kidney disease may prefer semaglutide based on the FLOW trial data (Perkovic et al., New England Journal of Medicine, 2024), which showed renal protection benefits.

The pattern we see most often: patients start with the medication their provider is most familiar with, then switch based on individual response. The "right" medication is the one that produces acceptable weight loss with tolerable side effects at a sustainable cost. That calculation is individual.

Brand name confusion: Mounjaro vs Zepbound vs Ozempic vs Wegovy

The brand-name landscape creates additional confusion:

Brand name	Active ingredient	FDA-approved indication	Typical dose
Mounjaro	Tirzepatide	Type 2 diabetes	5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly
Zepbound	Tirzepatide	Obesity	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly
Ozempic	Semaglutide	Type 2 diabetes	0.25 mg, 0.5 mg, 1 mg, 2 mg weekly
Wegovy	Semaglutide	Obesity	0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly
Rybelsus	Semaglutide	Type 2 diabetes	3 mg, 7 mg, 14 mg daily (oral)

Mounjaro and Zepbound contain identical active ingredients at identical doses. The brand distinction exists purely for FDA regulatory and insurance billing purposes. Ozempic and Wegovy similarly contain identical active ingredients; Wegovy is dosed higher (up to 2.4 mg vs 2 mg max for Ozempic).

Patients often receive a Mounjaro prescription for weight loss (off-label use) or a Zepbound prescription for diabetes (off-label use) depending on which indication their insurance covers. The medication is the same.

The correct answer to "Is Mounjaro the same as Ozempic?" is no. Mounjaro contains tirzepatide; Ozempic contains semaglutide. They are different molecules. The correct answer to "Is Mounjaro the same as Zepbound?" is yes, identical active ingredient and formulation.

When semaglutide might be the better choice

Tirzepatide shows superior weight-loss efficacy in clinical trials, but semaglutide remains the better choice for specific patient populations:

1. Patients with established cardiovascular disease.

Semaglutide has proven cardiovascular risk reduction in the SUSTAIN-6 trial (3-point MACE reduction: HR 0.74, 95% CI 0.58-0.95). Tirzepatide's cardiovascular outcomes data is pending. For patients with prior MI, stroke, or peripheral artery disease, semaglutide's established cardioprotective benefit outweighs tirzepatide's incremental weight-loss advantage.

2. Patients with chronic kidney disease.

The FLOW trial (Perkovic et al., New England Journal of Medicine, 2024) demonstrated that semaglutide reduced the risk of kidney failure, cardiovascular death, and major kidney events by 24% in patients with type 2 diabetes and CKD. Tirzepatide has shown favorable effects on albuminuria in SURPASS trials but lacks dedicated renal outcomes data.

3. Patients who experienced intolerable side effects on tirzepatide.

About 6% of tirzepatide users discontinue due to gastrointestinal side effects (nausea, vomiting, diarrhea) compared to 4% of semaglutide users. Patients who cannot tolerate tirzepatide often tolerate semaglutide, likely because the GIP receptor component contributes to nausea in susceptible individuals.

4. Patients seeking oral administration.

Semaglutide is available as Rybelsus, an oral daily tablet. Tirzepatide has no oral formulation. Patients with needle phobia or preference for oral medication have no tirzepatide option.

5. Patients prioritizing cost in the compounded market.

Compounded semaglutide has been available longer and is produced by more compounding pharmacies, which creates price competition. During periods of high demand, compounded semaglutide is often $50 to $100 per month cheaper than compounded tirzepatide. For patients paying out of pocket, the cost difference may outweigh the efficacy difference.

The decision is not "tirzepatide is better, full stop." The decision is "which medication's benefit-risk-cost profile fits this patient's clinical situation and priorities."

The compounded medication landscape for both molecules

Both semaglutide and tirzepatide are available as compounded medications from licensed U.S. compounding pharmacies. Compounded versions are not FDA-approved and are not interchangeable with brand-name products.

Compounded semaglutide:

• Available since mid-2022 during Ozempic and Wegovy shortages
• Typically compounded as lyophilized powder requiring reconstitution with bacteriostatic water
• Dosed in milligrams matching brand-name dosing schedules (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly)
• Some formulations include vitamin B12 (cyanocobalamin or methylcobalamin) to address potential B12 deficiency from chronic GLP-1 therapy
• Cost range: $200 to $400 per month depending on dose and pharmacy

Compounded tirzepatide:

• Available since late 2022 during Mounjaro shortages
• Compounded as lyophilized powder requiring reconstitution
• Dosed in milligrams matching brand-name schedules (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly)
• Some formulations include B12
• Cost range: $250 to $450 per month depending on dose and pharmacy

Both compounded medications require proper storage (refrigeration), sterile reconstitution technique, and subcutaneous injection. FormBlends provides detailed reconstitution and injection protocols with every prescription.

The legal basis for compounding: Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacies to compound medications in response to individual prescriptions when a licensed provider determines compounding is medically necessary. The FDA has not taken enforcement action against compounded semaglutide or tirzepatide as of April 2026, and both remain on the FDA drug shortage list, which permits compounding under 503A.

Patients considering compounded versions should understand: compounded medications have not undergone FDA review for safety, efficacy, or quality. They are prepared by individual pharmacies under state pharmacy board oversight. Quality varies by pharmacy. FormBlends works exclusively with FDA-registered 503A facilities that follow USP <797> sterile compounding standards.

For detailed guidance on compounded semaglutide, see our article on compounded semaglutide safety and efficacy.

Side effect profiles: how they differ in practice

Both medications share a common side effect profile driven by GLP-1 receptor activation: nausea, vomiting, diarrhea, constipation, abdominal pain, and delayed gastric emptying. The incidence and severity differ modestly.

Nausea:

• Semaglutide 2.4 mg: 44% of patients in STEP 1 trial
• Tirzepatide 15 mg: 33% of patients in SURMOUNT-1 trial

The lower nausea rate with tirzepatide is counterintuitive given its dual mechanism. The likely explanation: GIP receptor activation may reduce nausea signaling in the brainstem, partially offsetting the nausea caused by GLP-1 activation. This hypothesis is supported by preclinical models but not yet proven in humans.

Vomiting:

• Semaglutide 2.4 mg: 24% in STEP 1
• Tirzepatide 15 mg: 18% in SURMOUNT-1

Diarrhea:

• Semaglutide 2.4 mg: 30% in STEP 1
• Tirzepatide 15 mg: 23% in SURMOUNT-1

Constipation:

• Semaglutide 2.4 mg: 24% in STEP 1
• Tirzepatide 15 mg: 17% in SURMOUNT-1

Discontinuation due to gastrointestinal side effects:

• Semaglutide 2.4 mg: 4.5% in STEP 1
• Tirzepatide 15 mg: 6.2% in SURMOUNT-1

The pattern: tirzepatide has lower rates of individual GI side effects but a slightly higher discontinuation rate. The explanation likely involves the severity distribution: tirzepatide may cause less frequent but more severe GI symptoms in the subset of patients who experience them.

Injection site reactions:

• Semaglutide: 2-3% across trials
• Tirzepatide: 2-4% across trials

Comparable and low for both.

Pancreatitis:

Both medications carry a black-box warning for potential pancreatitis risk. Incidence in clinical trials:

• Semaglutide: 0.2% to 0.3%
• Tirzepatide: 0.2% to 0.4%

The risk is low but real. Patients with a history of pancreatitis should discuss the risk-benefit calculation with their provider.

Gallbladder disease:

Rapid weight loss from any cause increases gallstone risk. Both medications show elevated cholelithiasis rates:

• Semaglutide: 1.6% in STEP 1
• Tirzepatide: 2.2% in SURMOUNT-1

The difference likely reflects the greater weight-loss velocity with tirzepatide rather than a direct drug effect.

Thyroid C-cell tumors:

Both medications carry a boxed warning based on rodent studies showing medullary thyroid carcinoma. No human cases have been causally linked to either medication in over 15 years of semaglutide use and 4 years of tirzepatide use. The warning remains because the rodent signal has not been definitively ruled out in humans.

For a detailed protocol on managing nausea and gastrointestinal side effects, see our article on managing GLP-1 side effects.

Cost and insurance coverage differences

Brand-name pricing (list price, before insurance):

• Mounjaro: $1,069 per month
• Zepbound: $1,059 per month
• Ozempic: $969 per month
• Wegovy: $1,349 per month

List prices are nearly irrelevant. Actual patient cost depends on insurance coverage, manufacturer copay cards, and pharmacy benefit design.

Insurance coverage patterns:

For diabetes: Most commercial insurance plans cover Mounjaro and Ozempic with prior authorization. Tier placement varies (typically tier 3 or specialty tier). Medicare Part D covers both.

For obesity: Coverage is inconsistent. Many commercial plans exclude obesity medications entirely. Plans that do cover obesity drugs typically require BMI ≥30 (or ≥27 with comorbidities), prior authorization, and step therapy (trying older medications first). Medicare Part D does not cover obesity medications by statute.

Manufacturer copay assistance:

• Eli Lilly offers copay cards reducing Mounjaro and Zepbound to as low as $25 per month for commercially insured patients
• Novo Nordisk offers copay cards reducing Ozempic and Wegovy to as low as $25 per month for commercially insured patients

Copay cards are not available for Medicare, Medicaid, or uninsured patients.

Compounded medication pricing:

• Compounded semaglutide: $200 to $400 per month
• Compounded tirzepatide: $250 to $450 per month

Compounded versions are not covered by insurance. Patients pay out of pocket. HSA and FSA funds can typically be used.

The cost calculation for most patients: if insurance covers brand-name medication with a copay card, brand-name is cheaper ($25 to $50 per month). If insurance doesn't cover or the copay is high (>$300 per month), compounded versions are cheaper.

The decision framework: which medication for which patient

Choose semaglutide if:

• Patient has established cardiovascular disease and would benefit from proven MACE reduction
• Patient has chronic kidney disease and would benefit from proven renal protection
• Patient prefers or requires oral administration (Rybelsus)
• Patient previously tried tirzepatide and experienced intolerable nausea or vomiting
• Cost is the primary concern and compounded semaglutide is significantly cheaper in your region

Choose tirzepatide if:

• Patient's primary goal is maximum weight loss and they have no contraindications
• Patient has high baseline BMI (35+) and needs aggressive intervention
• Patient previously used semaglutide and plateaued or had inadequate weight loss
• Patient tolerates GI side effects well and prioritizes efficacy over tolerability
• Patient has no cardiovascular or renal disease requiring proven risk reduction

The neutral zone (either medication is reasonable):

• Patient is starting GLP-1 therapy for the first time with no strong clinical factors favoring one over the other
• Patient has type 2 diabetes without cardiovascular or renal complications
• Patient has obesity without significant comorbidities

In the neutral zone, the choice defaults to provider familiarity, patient preference, and cost. There is no wrong answer. Both medications work. The "best" medication is the one the patient will take consistently for 12+ months.

FAQ

Is Mounjaro the same as semaglutide? No. Mounjaro contains tirzepatide, a GLP-1/GIP dual receptor agonist. Semaglutide is a different molecule that activates only GLP-1 receptors. Semaglutide is found in Ozempic, Wegovy, and Rybelsus. They are not interchangeable.

Which is better for weight loss, Mounjaro or semaglutide? Tirzepatide (Mounjaro, Zepbound) produces greater weight loss in clinical trials. SURPASS-2 showed tirzepatide produced 6.2 kg (13.6 lbs) more weight loss than semaglutide at 40 weeks. Real-world data shows similar patterns. Individual response varies.

Can I switch from Ozempic to Mounjaro? Yes, but it requires a new prescription and a different dosing schedule. Ozempic contains semaglutide; Mounjaro contains tirzepatide. Your provider will determine the appropriate starting dose of tirzepatide based on your current semaglutide dose and response. Do not switch without provider guidance.

Does Mounjaro have semaglutide in it? No. Mounjaro contains only tirzepatide. It does not contain semaglutide or any other active ingredient. The confusion arises because both medications are used for similar purposes (diabetes and weight loss), but the active ingredients are completely different.

Is tirzepatide stronger than semaglutide? Tirzepatide produces greater weight loss and A1C reduction in head-to-head trials, which suggests greater potency for those outcomes. "Stronger" is not a precise pharmacological term. Both medications are effective; tirzepatide shows superior efficacy in most clinical endpoints.

Why is Mounjaro called a GLP-1 medication if it's tirzepatide? Tirzepatide is technically a GLP-1/GIP dual agonist, not a pure GLP-1 agonist. The term "GLP-1 medication" is often used colloquially to describe the entire class of incretin-based therapies, which includes both pure GLP-1 agonists (semaglutide, liraglutide) and dual agonists (tirzepatide). It's imprecise but common.

Can I take Mounjaro and Ozempic together? No. Combining tirzepatide and semaglutide is not recommended. Both medications slow gastric emptying and activate overlapping pathways. Combining them increases the risk of severe nausea, vomiting, and gastroparesis without meaningful additional benefit. Use one or the other, not both.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and is not manufactured by Eli Lilly. Compounded versions are prepared by state-licensed pharmacies and have not undergone the same safety and efficacy review as brand-name Mounjaro. They are not interchangeable.

Does tirzepatide work faster than semaglutide? Both medications reach steady-state concentration after 4 to 5 weeks of weekly dosing. Weight loss begins within the first 4 weeks for both. Tirzepatide produces more total weight loss over time, but the time to initial response is comparable.

Which has fewer side effects, Mounjaro or Ozempic? Tirzepatide has lower rates of nausea, vomiting, and diarrhea in clinical trials compared to semaglutide at maximum doses. However, tirzepatide has a slightly higher discontinuation rate (6.2% vs 4.5%), suggesting that when side effects occur, they may be more severe. Individual tolerance varies.

Is Mounjaro approved for weight loss? Mounjaro (tirzepatide) is FDA-approved only for type 2 diabetes. Zepbound, which contains the same active ingredient (tirzepatide), is FDA-approved for obesity. Providers may prescribe Mounjaro off-label for weight loss. Compounded tirzepatide is prescribed for weight loss when brand-name options are not accessible.

Can I use semaglutide if tirzepatide is on backorder? Yes. Semaglutide is a reasonable alternative if tirzepatide is unavailable. Your provider will determine the appropriate semaglutide dose based on your treatment goals. The medications are not interchangeable dose-for-dose, so do not attempt to convert doses without provider guidance.

Sources

1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Lingvay I et al. Comparative effectiveness of tirzepatide and semaglutide for weight loss in adults with type 2 diabetes: A real-world evidence study. JAMA Internal Medicine. 2024.
6. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
7. Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW trial). New England Journal of Medicine. 2024.
8. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: gastric emptying substudy. Diabetes Care. 2023.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
10. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Diabetes, Obesity and Metabolism. 2023.
11. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
13. FDA. Drug Shortages Database. Accessed April 2026.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.